Recent executive action and administrative steps have accelerated federal marijuana rescheduling under the Controlled Substances Act. In December 2025, an executive order directed the Department of Justice to expedite moving marijuana from Schedule I to Schedule III. This led to an April 2026 order immediately placing FDA-approved marijuana products and those under state medical marijuana licenses into Schedule III, while withdrawing prior proceedings and launching an expedited hearing process. The hearing is scheduled to begin June 29, 2026, to evaluate broader rescheduling that could encompass additional forms of marijuana. These developments have shaped trader assessments of timelines, with the hearing date serving as a key near-term catalyst for potential further movement in scheduling status.
Eksperimental na AI-generated summary na nire-reference ang Polymarket data. Hindi ito trading advice at wala itong papel sa kung paano nire-resolve ang market na ito. · Na-update$760,402 Vol.
June 30
3%
December 31
28%
$760,402 Vol.
June 30
3%
December 31
28%
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Binuksan ang Market: Feb 7, 2026, 5:04 PM ET
Resolver
0x65070BE91...The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Resolver
0x65070BE91...Recent executive action and administrative steps have accelerated federal marijuana rescheduling under the Controlled Substances Act. In December 2025, an executive order directed the Department of Justice to expedite moving marijuana from Schedule I to Schedule III. This led to an April 2026 order immediately placing FDA-approved marijuana products and those under state medical marijuana licenses into Schedule III, while withdrawing prior proceedings and launching an expedited hearing process. The hearing is scheduled to begin June 29, 2026, to evaluate broader rescheduling that could encompass additional forms of marijuana. These developments have shaped trader assessments of timelines, with the hearing date serving as a key near-term catalyst for potential further movement in scheduling status.
Eksperimental na AI-generated summary na nire-reference ang Polymarket data. Hindi ito trading advice at wala itong papel sa kung paano nire-resolve ang market na ito. · Na-update
Mag-ingat sa mga external link.
Mag-ingat sa mga external link.
Mga Madalas na Tanong